Drug Profile

Tri specific fusion protein targeting PD-1 VEGF and IL-2 Variant - Mustbio

Latest Information Update: 29 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Must Bio
Class Antineoplastics; Recombinant fusion proteins; Trispecific antibodies
Mechanism of Action B7-H1 antigen inhibitors; Interleukin 2 receptor agonists; Vascular endothelial growth factor A inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

25 Apr 2025 Preclinical trials in Cancer in South Korea (Parenteral)
25 Apr 2025 Pharmacodynamics data from a preclinical study in solid tumours presented at the 116^th American Association for Cancer Research Annual Meeting (AACR-2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com